NOVAVAX INC Convertible Notes Payable
NOVAVAX INC (NVAX) had Convertible Notes Payable of $169.68 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified
us-gaap:ConvertibleNotesPayable · last filed 2025-02-27
- 2024-12-31: Convertible Notes Payable $169.68M.
- 2023-12-31: Convertible Notes Payable $168.02M.
- 2022-09-30: Convertible Notes Payable $324.52M.
- 2022-06-30: Convertible Notes Payable $324.17M.
| Period end | Convertible Notes Payable |
|---|---|
| 2024-12-31 | $169.68M 10-K · filed 2025-02-27 |
| 2023-12-31 | $168.02M 10-K · filed 2025-02-27 |
| 2022-09-30 | $324.52M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $324.17M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $323.81M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $323.46M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |